313 results
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
16 Aug 21
Other Events
4:15pm
in the study, sparsentan has been generally well-tolerated and consistent with the observed safety profile to date. Based on the results from the interim … analysis are expected in the second half of 2023.
A preliminary review of the interim safety results indicate sparsentan has been generally well
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Jun 11
Regulation FD Disclosure
12:00am
Developments (2 of 2)
Full ITP Approval Granted by FDA
GSK completed post-approval commitment of generating long-term safety
data
Label now includes … efficacy and safety data from RAISE, 6-month ITP study
Since 2008, GSK has been working with FDA. Studies submitted:
6-month efficacy and safety data
2
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Nov 12
Other Events
12:00am
the initiation of interferon therapy or limits the ability to maintain optimal interferon-based therapy; and
Safety and efficacy have not been … utilized peginterferon alfa-2b (PEGINTRON®) plus ribavirin.
Important Safety Information for PROMACTA
BOXED WARNING
PROMACTA may cause hepatotoxicity
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Jun 11
Regulation FD Disclosure
12:00am
Developments (2 of 2)
Full ITP Approval Granted by FDA
GSK completed post-approval commitment of generating long-term safety
data
Label now includes … efficacy and safety data from RAISE, 6-month ITP study
Since 2008, GSK has been working with FDA. Studies submitted:
6-month efficacy and safety data
2
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Jun 10
Regulation FD Disclosure
12:00am
findings in general indicate exposure increases with
dose with wide variability
No safety signals of concern in this initial short term study …
Safety and efficacy data supports further investigation of eltrombopag
in this patient population
2 parallel global Phase III studies
Eltrombopag
8-K
EX-99.2
txex30qpoqb
23 Jun 11
Regulation FD Disclosure
12:00am
425
he970o
23 Nov 09
Business combination disclosure
12:00am
8-K
EX-99.1
a1jkm5egkwyrpp9hp
23 Nov 09
Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033
12:00am
8-K
EX-99.1
wb6fw9v 9csnx0d
6 May 20
Ligand Reports First Quarter 2020 Financial Results
4:03pm
8-K
EX-99.1
vza7is
22 Jun 11
Product has Potential to Offer Important Advantages Over Current IV Melphalan
12:00am
8-K
EX-99.1
7x50h0knxsq0
18 Nov 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
dymghp ez3
22 Jul 13
Ligand Signs Global License Agreement with Azure for Lasofoxifene
12:00am